The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Divergent CSF alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy
Open accessAbstract
BACKGROUND: Elevated CSF τ is considered a biomarker of neuronal injury in newly developed Alzheimer's disease (AD) and mild cognitive impairment (MCI) criteria. However, previous studies have failed to detect alterations of τ species in other primary tauopathies. We assessed CSF τ protein abnormalities in AD, a tauopathy with prominent Aβ pathology, and progressive supranuclear palsy (PSP), a primary tauopathy characterised by deposition of four microtubule-binding repeat (4R) τ with minimal Aβ pathology. METHODS: 26 normal control (NC), 37 AD, and 24 patients with PSP participated in the study. AD and PSP were matched for severity using the clinical dementia rating sum of boxes (CDR-sb) scores. The INNO BIA AlzBio3 multiplex immunoassay was used to measure CSF Aβ, total τ, and ptau181. Additional, novel ELISAs targeting different N-terminal and central τ epitopes were developed to examine CSF τ components and to investigate interactions between diagnostic group, demographics and genetic variables. RESULTS: PSP had lower CSF N-terminal and C-terminal τ concentrations than NC and AD measured with the novel τ ELISAs and the standard AlzBio3 τ and ptau assays. AD had higher total τ and ptau levels than NC and PSP. There was a gender by diagnosis interaction in AD and PSP for most τ species, with lower concentrations for male compared to female patients. CONCLUSIONS: CSF τ fragment concentrations are different in PSP compared with AD despite the presence of severe τ pathology and neuronal injury in both disorders. CSF τ concentration likely reflects multiple factors in addition to the degree of neuronal injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Experimental — accuracy not yet measuredIn the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,680
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Delis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Self-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Cited by
Sorted by citations
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485
Self-citationTau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
Schöll, M., Maaß, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. J. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 248
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 185
Self-citationDetection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles
Guix, F. X., Corbett, G. T., Cha, D., Mustapić, M., Liu, W., Mengel, D., Chen, Z., Aïkawa, E., Young‐Pearse, T. L., Kapogiannis, D., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030663 · Cited by 186
Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers
Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170
MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways
El Fatimy, R., Li, S., Chen, Z., Mushannen, T., Gongala, S., Wei, Z., Balu, D. T., Rabinovsky, R., Cantlon, A., Elkhal, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1880-5 · Cited by 161
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168
Kanmert, D., Cantlon, A., Muratore, C., Jin, M., O’Malley, T. T., Lee, G. S., Young‐Pearse, T. L., Selkoe, D. J., & Walsh, D. M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0387-15.2015 · Cited by 169
Dam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 152
Self-citationEvolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
Stamelou, M., Respondek, G., Giagkou, N., Whitwell, J. L., Kovács, G. G., & Höglinger, G. U. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00541-5 · Cited by 149
Boxer, A. L., Qureshi, I., Ahlijanian, M. K., Grundman, M., Golbe, L. I., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O’Suilleabhain, P. E., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 143
Self-citationMattsson, N., Grinberg, L. T., Boxer, A. L., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A. J., Spina, S., Janelidze, S., Rojas-Martinex, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200040 · Cited by 141
Self-citationExpression of A152T human tau causes age‐dependent neuronal dysfunction and loss in transgenic mice
Maeda, S., Djukic, B., Taneja, P., Yu, G.-Q., Lo, I., Davis, A., Craft, R., Guo, W., Wang, X., Kim, D., et al. (2016) · EMBO Reports · doi:10.15252/embr.201541438 · Cited by 133
Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease
Jiang, L., Dong, H., Cao, H., Ji, X., Luan, S., & Liu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.914027 · Cited by 130
Barthélemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01001 · Cited by 123
Chen, Z., Mengel, D., Keshavan, A., Rissman, R. A., Billinton, A., Perkinton, M. S., Percival‐Alwyn, J., Schultz, A. P., Properzi, M. J., Johnson, K. A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.010 · Cited by 114
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., Boxer, A. L., AL-108-231 Investigators, Williams, D. R., Lafontaine, A. L., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004859 · Cited by 113
Self-citationAnti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100
Self-citationCSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L. A., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 99
Self-citationCurrent Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Vogels, T., Leuzy, A., Cicognola, C., Ashton, N. J., Smolek, T., Novák, M., Blennow, K., Zetterberg, H., Hromádka, T., Žilka, N., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.019 · Cited by 99
Clinical Approach to Progressive Supranuclear Palsy
Ling, H. (2016) · Journal of Movement Disorders · doi:10.14802/jmd.15060 · Cited by 96
Progressive Supranuclear Palsy: an Update
Armstrong, M. J. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0819-5 · Cited by 95
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90
Self-citationSex Differences in Autophagy Contribute to Female Vulnerability in Alzheimer's Disease
Congdon, E. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00372 · Cited by 80
Tau immunotherapies for Alzheimer’s disease
Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y. M., & Decourt, B. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1619694 · Cited by 69
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 71
Lebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 77
Clinical Spectrum of Tauopathies
Olfati, N., Shoeibi, A., & Litvan, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.944806 · Cited by 66
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Kolen, K. V., Theunis, C., Mercken, M. H., & Kolb, H. C. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 63
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 65
Tau Secretion: Good and Bad for Neurons
Pernègre, C., Duquette, A., & Leclerc, N. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00649 · Cited by 70
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
Koziorowski, D., Figura, M., Milanowski, Ł., Szlufik, S., Alster, P., Madetko‐Alster, N., & Friedman, A. (2021) · Cells · doi:10.3390/cells10030656 · Cited by 59
Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation
Cohen, T. J., Constance, B. H., Hwang, A. W., James, M., & Yuan, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158470 · Cited by 58
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Snellman, A., Lantero‐Rodriguez, J., Emeršič, A., Vrillon, A., Karikari, T. K., Ashton, N. J., Kramberger, M. G., Čučnik, S., Paquet, C., Rot, U., et al. (2021) · Brain · doi:10.1093/brain/awab481 · Cited by 54
Florenzano, F., Corsetti, V., Ciasca, G., Ciotti, M. T., Pittaluga, A., Olivero, G., Feligioni, M., Iannuzzi, F., Latina, V., Sciacca, M. F. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17371 · Cited by 54
Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases
Seino, Y., Nakamura, T., Kawarabayashi, T., Hirohata, M., Narita, S., Wakasaya, Y., Kaito, K., Ueda, T., Harigaya, Y., & Shoji, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181152 · Cited by 50
Genome-wide association study identifies MAPT locus influencing human plasma tau levels
Chen, J., Yu, J., Wojta, K. J., Wang, H.-F., Zetterberg, H., Blennow, K., Yokoyama, J. S., Weiner, M. W., Kramer, J. H., Rosen, H. J., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003615 · Cited by 46
Self-citationMah, D., Zhao, J., Liu, X., Zhang, F., Liu, J., Wang, L., Linhardt, R. J., & Wang, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671458 · Cited by 53
Blömeke, L., Pils, M., Kraemer‐Schulien, V., Dybala, A., Schaffrath, A., Kulawik, A., Rehn, F., Cousin, A., Nischwitz, V., Willbold, J., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00330-x · Cited by 43
Amadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 44
Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 38
Sarnowski, C., Ghanbari, M., Bis, J. C., Logue, M. W., Fornage, M., Mishra, A., Ahmad, S., Beiser, A., Boerwinkle, E., Bouteloup, V., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03287-y · Cited by 39
Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 42
Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
La‐Rocque, S. D., Moretto, E., Butnaru, I., & Schiavo, G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 46
Frontrunner in Translation: Progressive Supranuclear Palsy
Shoeibi, A., Olfati, N., & Litvan, I. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01125 · Cited by 39
Borroni, B., Benussi, A., Premi, E., Alberici, A., Marcello, E. E., Gardoni, F., Luca, M. D., & Padovani, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170584 · Cited by 41
Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., Scalise, S., Colona, V. L., Imbriani, P., Mercuri, N. B., Bernardini, S., Lang, A. E., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1893-1 · Cited by 36
Batra, R., Krumsiek, J., Wang, X., Allen, M., Blach, C., Kastenmüller, G., Arnold, M., Ertekin‐Taner, N., & Kaddurah‐Daouk, R. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14249 · Cited by 36
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 33
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 32
Jabbari, E., Zetterberg, H., & Morris, H. R. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315857 · Cited by 31
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30
Blood based biomarkers for movement disorders
Morris, H. R. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13700 · Cited by 29
Progressive Supranuclear Palsy Syndrome: An Overview
Ichikawa-Escamilla, E., Velasco-Martínez, R. A., & Adalid-Peralta, L. V. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.04.008 · Cited by 31
Sjödin, S., Hansson, O., Öhrfelt, A., Brinkmalm, G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700100 · Cited by 26
Key emerging issues in progressive supranuclear palsy and corticobasal degeneration
Josephs, K. A. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7682-y · Cited by 25
Benussi, A., Dell’Era, V., Cantoni, V., Turrone, R., Pilotto, A., Alberici, A., Cotelli, M. S., Rizzetti, M. C., Padovani, A., & Borroni, B. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.05.017 · Cited by 25
The Progressive Supranuclear Palsy: Past and Present Aspects
Parthimos, T. P., & Schulpis, K. H. (2019) · Clinical Gerontologist · doi:10.1080/07317115.2019.1694115 · Cited by 25
Dilcher, R., Wall, S., Groß, M., Katzdobler, S., Wagemann, O., Palleis, C., Weidinger, E., Fietzek, U. M., Bernhardt, A., Kurz, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14185 · Cited by 23
Campese, N., Palermo, G., Gamba, C. D., Beatino, M. F., Galgani, A., Belli, E., Prete, E. D., Vecchia, A. D., Vergallo, A., Siciliano, G., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1886929 · Cited by 23
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
Sato, C., Mallipeddi, N., Ghoshal, N., Wright, B. A., Day, G. S., Davis, A. A., Kim, A. H., Zipfel, G. J., Bateman, R. J., Gabelle, A., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51435 · Cited by 21
Cognitive dysfunction in corticobasal degeneration
de Oliveira, L. M., Barcellos, I., Teive, H. A. G., & Munhoz, R. P. (2017) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20170077 · Cited by 26
Chen, Y., Huang, J., Li, Y., Chen, X., & Ye, Q. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119975 · Cited by 22
Higher Cerebrospinal Fluid Biomarkers of Neuronal Injury in Hiv-Associated Neurocognitive Impairment
Ellis, R. J., Chenna, A., Petropoulos, C. J., Lie, Y., Curanović, D., Crescini, M., Winslow, J. W., Sundermann, E. E., Tang, B., & Letendre, S. L. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-022-01081-4 · Cited by 21
Triana‐Baltzer, G., Kolen, K. V., Theunis, C., Moughadam, S., Slemmon, R., Mercken, M. H., Galpern, W. R., Sun, H. F., & Kolb, H. C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200463 · Cited by 23
Borreca, A., Latina, V., Corsetti, V., Middei, S., Piccinin, S., Valle, F. D., Bussani, R., Ammassari‐Teule, M., Nisticò, R., Calissano, P., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0974-3 · Cited by 18
Atypical parkinsonism – new advances
Stamelou, M., & Bhatia, K. P. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000355 · Cited by 18
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review
Dunning, E. E., Decourt, B., Zawia, N. H., Shill, H. A., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00614-9 · Cited by 20
The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis
Raimo, S., Gaita, M., Cropano, M., Mautone, G., D’Iorio, A., Trojano, L., & Santangelo, G. (2022) · Neuropsychology Review · doi:10.1007/s11065-022-09551-6 · Cited by 17
Cicognola, C., Hansson, O., Scheltens, P., Kvartsberg, H., Zetterberg, H., Teunissen, C. E., & Blennow, K. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00756-6 · Cited by 16
Hauer, K. O., Pawlik, D., Leuzy, A., Janelidze, S., Hall, S., Hansson, O., & Smith, R. A. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.11.018 · Cited by 15
Foster, K., Manca, M., McClure, K. F., Koivula, P. P., Trojanowski, J. Q., Havas, D., Chancellor, S. E., Goldstein, L. E., Brunden, K. R., Kraus, A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13028 · Cited by 15
Self-citationOne decade ago, one decade ahead in progressive supranuclear palsy
Stamelou, M., Giagkou, N., & Höglinger, G. U. (2019) · Movement Disorders · doi:10.1002/mds.27788 · Cited by 14
Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis
Ito, D. (2021) · Annals of Neurology · doi:10.1002/ana.26259 · Cited by 15
Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials
Marotta, C., Sinclair, B., O'Brien, T. J., & Vivash, L. E. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf022 · Cited by 14
On-chip microtubule gliding assay for parallel measurement of tau protein species
Parimalam, S. S., Tarhan, M. C., Karsten, S. L., Fujita, H., Shintaku, H., Kotera, H., & Yokokawa, R. (2016) · Lab on a Chip · doi:10.1039/c5lc01486g · Cited by 13
Granadillo, E. D., Paholpak, P., Mendez, M. F., & Teng, E. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477718 · Cited by 13
NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression
Mengel, D., Mok, T. H., Nihat, A., Liu, W., Rissman, R. A., Galasko, D., Zetterberg, H., Mead, S., Collinge, J., & Walsh, D. M. (2021) · Cells · doi:10.3390/cells10123514 · Cited by 12
Tau Diagnostics and Clinical Studies
Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes
Giannakis, A., Sioka, C., Kloufetou, E., & Konitsiotis, S. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02865-0 · Cited by 11
Giannakis, A., Konitsiotis, S., & Sioka, C. (2025) · Medicina · doi:10.3390/medicina61040701 · Cited by 12
Quantitative Methods for the Detection of Tau Seeding Activity in Human Biofluids
Lathuilière, A., & Hyman, B. T. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.654176 · Cited by 13
Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy
Simoes, F. A., Joilin, G., Peters, O., Schneider, L., Priller, J., Spruth, E. J., Vogt, I. R., Kimmich, O., Spottke, A. E., Hoffmann, D. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314554 · Cited by 10
Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson’s Disease
Cristiani, C. M., Scaramuzzino, L., Quattrone, A., Parrotta, E. I., Cuda, G., & Quattrone, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136882 · Cited by 10
Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review
Macedo, A. C., Mariano, L. I., Martins, M. I., Friedlaender, C. V., Balbino, J. M. V., Rocha, J. V. D. F., Camargos, S., Cardoso, F., Caramelli, P., & de Souza, L. C. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13435 · Cited by 10
Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid
Jang, Y., Oh, S., Hall, A. J., Zhang, Z., Tropea, T. F., Chen‐Plotkin, A. S., Rosenthal, L. S., Dawson, T. M., Na, C. H., & Pantelyat, A. Y. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09507-3 · Cited by 10
Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias
Llorens, F., Villar‐Piqué, A., Candelise, N., Ferrer, I., & Zerr, I. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73528 · Cited by 10
Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism
Cerroni, R., Liguori, C., Stefani, A., Conti, M., Garasto, E., Pierantozzi, M., Mercuri, N. B., Bernardini, S., Fucci, G., & Massoud, R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00126 · Cited by 8
Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
Ishiguro, T., & Kasuga, K. (2024) · Brain Sciences · doi:10.3390/brainsci14090859 · Cited by 7
Eusébio, A., Koric, L., Félician, O., Guedj, E., Ceccaldi, M. P., & Azulay, J. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2016.07.009 · Cited by 7
Giagkou, N., Kapsali, I., Brinia, M.-E., & Constantinides, V. C. (2024) · Biomedicines · doi:10.3390/biomedicines12081781 · Cited by 7
Diagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers
Benussi A, B. B. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000168 · Cited by 6
Marques, T. M., van Rumund, A., Kuiperij, H. B., & Verbeek, M. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00007-1 · Cited by 6
Emerging drugs for progressive supranuclear palsy
Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives
Bougea, A. M., Colosimo, C., Falup‐Pecurariu, C., Palermo, G., & Değirmenci, Y. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02930-2 · Cited by 5
Oyeka, M., Ibilah, T., Israel, J., Gavito-Higuera, J., & Salazar, R. (2021) · Cureus · doi:10.7759/cureus.15641 · Cited by 4
Metadata
- Authors
- Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., Tartaglia, M. C., Miller, Z., Coppola, G., Ahlijanian, M., Soares, H., Kramer, J. H., Rabinovici, G. D., Rosen, H. J., Miller, B. L., Meredith, J., & Boxer, A. L.
- Affiliations
- University of California, San Francisco (US)
- Bristol-Myers Squibb (United States) (US)
- University of California, Los Angeles (US)
- Corresponding author
- Boxer, A. L.
- ORCID
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2014-06-04
- Volume
- 86
- Issue
- 3
- Pages
- 244-250
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC4256124
- OpenAlex
- W2133759450
- Cited by
- 132
- References
- 47
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 18 · 2023: 5 · 2022: 15 · 2021: 17 · 2020: 7 · 2019: 16 · 2018: 13 · 2017: 14 · 2016: 10 · 2015: 4 · 2014: 3
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (K23-AG031861)
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Hellman Family Foundation
- TauRx Pharmaceuticals
- Elan
- Kyowa Hakko Kirin
- H. Lundbeck A/S
- National Institutes of Health (AG19724)
- Genentech
- Avid Radiopharmaceuticals
- National Institute on Aging (AG031861, AG23501, R01AG022983, AG-19724, R01AG031278, K23AG031861, K24AG045333, R01AG038791, P01AG019724, R01AG032289, P50AG023501)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- tauopathy, Alzheimer's disease, progressive supranuclear palsy, cerebrospinal fluid tau, phosphorylated tau 181, amyloid-beta, 4R tau, sex differences, biomarkers, neuronal injury
- MeSH terms
- Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Peptide Fragments, Phosphorylation, Prognosis, Reference Values, Supranuclear Palsy, Progressive, Biomarkers, Amyloid beta-Peptides, tau Proteins, Tauopathies, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
